CARET: THE SEATTLE STUDY CENTER

CARET是一项正在进行的肺癌化学预防双盲试验 30 mgβ-胡萝卜素与25,000 mgβ-胡萝卜素潮汐联合治疗的疗效和安全性 每天在两个高危人群中使用维甲酸棕榈酸酯：(A)男性和 女性现任和前任吸烟者主要是从保险公司招募的 来源，以及(B)有大量职业石棉接触的男性 主要从基于就业的来源招聘。我们已经记录了 成功招募，出色的依从性，并将副作用降至最低 因此，超过15,000名参与者在六个研究中心随机选择毛皮。穿过 1993年4月30日，Caret随机选择了4000名接触石棉的工人， 超过所有五个Caret石棉中心的应计目标，以及11,105 烟瘾很大的人。西雅图和波特兰已经超过了他们的重度吸烟者 欧文正在按部就班地在1994年7月实现其目标。在.期间 在最后五年期间，Caret将专注于保留、遵守 协议、端点的确定、关键设计参数的监控、 试验的收尾、分析和发表。预测表明 有14,240名吸烟者和4,010名接触石棉的参与者以及 114,100人年的跟踪调查，截至1998年2月，Caret将 能够检测到两个国家的肺癌发病率降低了.23% 高危人群加在一起，减少了27%、49%、32%和35% 吸烟者、女性吸烟者、男性吸烟者和接触石棉的亚组， 分别进行了分析。 西雅图研究中心有独特的责任来遵循 最初吸烟者和暴露于石棉的工人试点的参与者 研究，以及西雅图在Caret疗效队列中的份额。中的 1985-1988年招募了1,845名飞行员参与者，1,524名(先锋 队列)继续积极参与。这些先锋参与者是 密切监测以评估可能与 研究中维生素的累积剂量。西雅图研究中心已经 超过了吸烟者和石棉的Caret功效招聘目标- 暴露的工人，部分原因是我们最近批准了招聘 美国退休人员协会的成员。学习中心 将继续强调留住参与者并遵守 卡雷特协议。终端的集合，这将增加 在过去的四年里，招聘也变得更加突出 活动停止。我们的数据和处理部门将专注于及时 向协调中心提交数据并进行核对。作为 最大的CARET研究中心，我们将在分析中发挥突出作用 和发布CARET结果。

CARET is an ongoing double-blind lung cancer chemoprevention trial of the efficacy and safety of tide combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate daily in two high-risk populations: (a) male and female current and former smokers recruited primarily from insurance-based sources, and (b)males with extensive occupational asbestos exposure recruited primarily from employment-based sources. We have documented successful recruitment, excellent adherence, and minimal side effects in over 15,000 participants randomized thus fur at six study centers. Through 30 April, 1993, CARET has randomized 4,000 asbestos-exposed workers, exceeding accrual goals at all five CARET asbestos centers, and 11,105 heavy smokers. Seattle and Portland have exceeded their heavy smoker goals, and Irvine is on track to achieve its goal in July 1994. During the final five-year period, CARET will focus on retention, adherence to protocol, ascertainment of endpoints, monitoring of key design parameters, closeout of the trial, and analysis and publication. Projections indicate that with 14,240 smokers and 4,010 asbestos-exposed participants and 114,100 person-years of follow-up through February 1998, CARET will be capable of detecting a. 23% reduction in lung cancer incidence in the two high-risk populations combined, and 27%, 49%, 32%, and 35% reductions in the smokers, female smokers, male smokers, and asbestos-exposed subgroups, respectively. The Seattle Study Center has a unique responsibility for following the participants in the original smoker and asbestos-exposed worker pilot studies, as well as Seattle's share of the CARET Efficacy cohort. Of the 1,845 Pilot participants recruited during 1985-1988, 1,524 (the Vanguard cohort) continued active participation. These Vanguard participants are monitored closely to evaluate toxicity potentially related to the cumulative dose of the study vitamins. The Seattle' Study Center has surpassed its CARET Efficacy recruitment goals of smokers and asbestos- exposed workers, in part due to our recently approved access to recruit members of the American Association of Retired Persons. The Study Center will continue to emphasize the retention of participants and adherence to the CARET protocol. The collection of endpoints, which will be increasing during the final four years, has also become more prominent as recruitment activities cease. Our data and processing unit will focus on timely submission and reconciliation of data with the Coordinating Center. As the largest study center of CARET, we will play a prominent role in analysis and publication of CARET results.